Want to see KR:004310 full AI Analyst Report?
Hyundai Pharmaceutical Co., Ltd. (004310) Financial Statements
Hyundai Pharmaceutical Co., Ltd. Financial Overview
Hyundai Pharmaceutical Co., Ltd.'s market cap is currently $203.12B. The company's EPS TTM is $120.84; its P/E ratio is 54.37; and it has a dividend yield of 0.46%. Hyundai Pharmaceutical Co., Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Nov 25 | Nov 24 | Nov 23 | Nov 22 | Nov 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 191.79B | $ 175.74B | $ 180.76B | $ 162.69B | $ 139.80B |
| Gross Profit | $ 78.23B | $ 73.37B | $ 75.24B | $ 68.84B | $ 56.31B |
| Operating Income | $ 3.30B | $ 180.89M | $ 6.93B | $ 7.97B | $ -1.57B |
| EBITDA | $ 7.58B | $ 3.94B | $ 13.21B | $ 10.04B | $ 670.96M |
| Net Income | $ 2.52B | $ -574.89M | $ 6.12B | $ -164.58M | $ -3.17B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 2.50B | $ 10.55B | $ 18.64B | $ 34.53B | $ 22.21B |
| Total Assets | $ 166.90B | $ 156.40B | $ 154.63B | $ 181.16B | $ 163.86B |
| Total Debt | $ 50.06B | $ 48.08B | $ 39.20B | $ 39.44B | $ 29.84B |
| Net Debt | $ 47.56B | $ 37.80B | $ 23.00B | $ 9.18B | $ 8.22B |
| Total Liabilities | $ 84.80B | $ 77.32B | $ 69.63B | $ 94.60B | $ 77.26B |
| Stockholders' Equity | $ 82.10B | $ 79.07B | $ 84.66B | $ 86.56B | $ 86.60B |
| Cash Flow | |||||
| Free Cash Flow | $ -4.73B | $ -13.56B | $ -10.65B | $ 5.04B | $ -1.68B |
| Operating Cash Flow | $ -123.29M | $ -2.37B | $ -4.55B | $ 11.62B | $ 5.13B |
| Investing Cash Flow | $ -8.37B | $ -9.66B | $ -3.09B | $ -9.99B | $ -27.75M |
| Financing Cash Flow | $ 720.97M | $ 6.10B | $ -6.43B | $ 7.01B | $ 3.25B |
Currency in KRW